Skip to Main Content

Paper Details

A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.
Clin Cancer Res
2
2022
Author NameAffiliation
Susana BanerjeeDivision of Clinical Studies, The Institute of Cancer Research
Susana BanerjeeThe Royal Marsden NHS Foundation Trust
Nina TunariuThe Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Nina TunariuThe Royal Marsden NHS Foundation Trust
Johann S de BonoThe Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
  • 1 - 5

Datasets

Release 1.2